Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

Cell Death Discovery

Volumn 1, Issue 1, 2015, Pages

  Berger, Sb ^a   Harris, P ^a   Nagilla, R ^a   Kasparcova, V ^a   Hoffman, S ^a   Swift, B ^a   Dare, L ^a   Schaeffer, M ^a   Capriotti, C ^a   Ouellette, M ^a   King, Bw ^a   Wisnoski, D ^a   Cox, J ^a   Reilly, M ^a   Marquis, Rw ^a   Bertin, J ^a   Gough, Pj ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84951172030     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2015.9     Document Type: Article

References (28)

1. Gentle IE, Wong WW, Evans JM, Bankovacki A, Cook WD, Khan NR et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. J Biol Chem 2011; 286: 13282–13291.
2. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M et al. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol 2004; 5: 503–507.
3. Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem 2005; 280: 36560–36566.
4. Lee TH, Shank J, Cusson N, Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem 2004; 279: 33185–33191.
5. Berger SB, Kasparcova V, Hoffman S, Swift B, Dare L, Schaeffer M et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014; 192: 5476–5480.
6. Newton K, Dugger DL, Wickliffe KE, Kapoor N, de Almagro MC, Vucic D et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014; 343: 1357–1360.
7. Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol 2014; 193: 1539–1543.
8. Takahashi N, Vereecke L, Bertrand MJM, Duprez L, Berger SB, Divert T et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 2014; 513: 95–99.
9. Dannappel M, Vlantis K, Kumari S, Polykratis A, Kim C, Wachsmuth L et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 2014; 513: 90–94.
10. Bonnet MC, Preukschat D, Welz PS, van LG, Ermolaeva MA, Bloch W et al. The adaptor protein FADD protects epidermal keratinocytes from necroptosis in vivo and prevents skin inflammation. Immunity 2011; 35: 572–582.
11. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011; 477: 335–339.
12. Degterev A, Hitomi J, Germscheid M, Ch'en IL, Korkina O, Teng X et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008; 4: 313–321.
13. Morioka S, Broglie P, Omori E, Ikeda Y, Takaesu G, Matsumoto K et al. TAK1 kinase switches cell fate from apoptosis to necrosis following TNF stimulation. J Cell Biol 2014; 204: 607–623.
14. Christofferson DE, Li Y, Hitomi J, Zhou W, Upperman C, Zhu H et al. A novel role for RIP1 kinase in mediating TNF[alpha] production. Cell Death Dis 2012; 3: e320.
15. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 2005; 1: 112–119.
16. Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S et al. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep 2015; 10: 1850–1860.
17. Fauster A, Rebsamen M, Huber KV, Bigenzahn JW, Stukalov A, Lardeau CH et al. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis 2015; 6: e1767.
18. Harris PA, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett 2013; 4: 1238–1243.
19. Cho Y, McQuade T, Zhang H, Zhang J, Chan FK. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One 2011; 6: e23209.
20. You Z, Savitz SI, Yang J, Degterev A, Yuan J, Cuny GD et al. Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab 2008; 28: 1564–1573.
21. Zhou Y, Dai W, Lin C, Wang F, He L, Shen M et al. Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Inflamm 2013; 2013: 706156.
22. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312–319.
23. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R et al. Structure–activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett 2005; 15: 5039–5044.
24. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-molecule inhibitor of RIP1 kinase. Cell Death Differ 2013; 20: 366.
25. Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway JB et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis 2012; 3: e437.
26. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 1998; 8: 297–303.
27. He S, Wang L, Miao L, Wang T, Du F, Zhao L et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009; 137: 1100–1111.
28. Weng D, Marty-Roix R, Ganesan S, Proulx MK, Vladimer GI, Kaiser WJ et al. Caspase-8 and RIP kinases regulate bacteria-induced innate immune responses and cell death. Proc Natl Acad Sci USA 2014; 111: 7391–7396.